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Congenital short QT syndrome (SQTS) is a repolarization disorder characterized by
abbreviated QT intervals, atrial and ventricular arrhythmias and a risk of sudden
death. This study characterized a missense mutation (I560T) in the S5 domain of
the hERG Kþ channel that has been associated with variant 1 of the SQTS.
Whole cell patch clamp recordings of wild-type (WT) and I560T hERG current
(IhERG) were made at 37 C from hERG expressing HEK 293 cells, and the
structural context of the mutation was investigated using a recently reported
cryo-EM structure of hERG. Under conventional voltage clamp, the I560T
mutation increased IhERG amplitude without altering the voltage-dependence of
activation, although it accelerated activation time-course and also slowed
deactivation time-course at some voltages. The voltage dependence of IhERG.e01429
lished by Elsevier Ltd. This is an open access article under the CC BY license
y/4.0/).
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inactivation was slowed by the I560T mutation. There was also a modest
decrease in Kþ over Naþ ion selectivity with the I560T mutation. Under action
potential (AP) voltage clamp, the net charge carried by hERG was signiﬁcantly
increased during ventricular, Purkinje ﬁbre and atrial APs, with maximal IhERG
also occurring earlier during the plateau phase of ventricular and Purkinje ﬁbre
APs. The I560T mutation exerted only a modest eﬀect on quinidine sensitivity of
IhERG: the IC50 for mutant IhERG was 2.3 fold that for WT IhERG under
conventional voltage clamp. Under AP voltage clamp the inhibitory eﬀect of 1
mM quinidine was largely retained for I560T hERG and the timing of peak
I560T IhERG was altered towards that of the WT channel. In both the open
channel structure and a closed hERG channel model based on the closely-related
EAG structure, I560T side-chains were oriented towards membrane lipid and
away from adjacent domains of the channel, contrasting with previous
predictions based on homology modelling. In summary, the I560T mutation
produces multiple eﬀects on hERG channel operation that result in a gain-of-
function that is expected to abbreviate ventricular, atrial and Purkinje ﬁbre
repolarization. Quinidine is likely to be of value in oﬀsetting the increase in
IhERG and altered IhERG timing during ventricular APs in SQTS with this mutation.
Keywords: Biophysics, Computational biology, Physiology
1. Introduction
Cardiac action potential (AP) repolarization is mediated by a number of distinct po-
tassium (Kþ) ion channels. The initial early repolarization phase involves transient
outward potassium current (Ito), the pore forming subunits of which are encoded by
KCND2, KCND3, and KCNA4 genes [1, 2]. Over AP plateau voltages the rapid and
slow delayed rectiﬁer Kþ currents (IKr and IKs) respectively play critical roles and are
therefore important determinants of AP duration, with pore-forming subunits en-
coded by hERG (human-Ether-a-go-go Related Gene, alternative nomenclature
KCNH2) and KCNQ1 [1,3]. Terminal repolarization is driven by inwardly rectifying
Kþ current (IK1), which also plays an important role in setting the resting potential in
non-pacemaker regions, through channels comprised of Kir2.x channel subunits [1,
2, 4]. In atrial myocytes an additional Kþ current, the ultrarapid delayed rectiﬁer,
IKur, is also important [1]. In the time since hERG was ﬁrst identiﬁed as underlying
the channels that mediate IKr [5, 6], loss-of-function hERG mutations have been
found to be responsible for the LQT2 form of congenital long QT syndrome
(LQTS), whilst the unique pharmacological promiscuity of the channel has been
implicated in drug-induced LQTS [7]. Since 2004, gain-of-function hERGmutations
have been found in congenital short QT syndrome (SQTS) [8, 9].on.2019.e01429
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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is characterised by: short rate corrected QT (QTc) intervals on the electrocardiogram;
poor rate adaptation of the QT interval; shortened eﬀective refractory periods; atrial
and ventricular arrhythmias and, often, by a history of sudden death in aﬀected fam-
ilies [9, 11, 12]. Mutations in a number of diﬀerent ion channel subunits have been
identiﬁed in SQTS patients, although a signiﬁcant proportion of patients with a
SQTS phenotype have not shown mutations in known candidate ion channels [9,
11, 12]. The ﬁrst successfully genotyped SQTS variant (SQT1) was found to involve
a gain-of-function mutation to hERG (N588K, located in the S5-Pore linker region)
in which voltage-dependent inactivation was greatly positive-shifted, resulting in a
substantial increase in IKr and a shift in its timing to earlier in the ventricular AP [8,
13, 14, 15]. The profound inactivation shift renders N588K-hERG channels and
SQT1 patients with this mutation comparatively insensitive to Class III antiar-
rhythmic drugs such as sotalol, whilst Class Ia drugs including quinidine and diso-
pyramide retain eﬀectiveness [8, 16, 17, 18]. A second hERG mutation (T618I;
located in the channel pore helix) produces a less profound shift in hERG current
(IhERG) inactivation [19, 20] and together with N588K, accounts for the majority
of successfully genotyped cases (respectively accounting for 25.9% and 18.5% of
genotyped cases; [9]). Several additional hERG mutations have been associated
with the syndrome (E50D; I560T; S631A; R1135H [12, 21, 22, 23]). The I560T mu-
tation was identiﬁed in a 64 year old male who presented with atrial ﬁbrillation and
ﬂutter and whose father and brother had died suddenly [12]. He had a QTc interval of
319 ms (heart rate of 68 beats min1); the I560T mutation, involving a residue
located in the S5 transmembrane helix, was due to a c1679T > C transition and
was absent in the genomic DNA of 200 controls [12]. Mature (fully glycosylated)
I560T hERG channels were found to express at similar levels to the wild-type
(WT) channel and limited in vitro biophysical characterisation showed an increase
in IhERG magnitude associated with a modest (þ14 mV) shift in steady-state voltage
dependence of inactivation [12]. Eﬀects of the mutation on time dependent proper-
ties of IhERG were not reported, nor was the sensitivity of I560T-hERG to antiar-
rhythmic agents reported. Prior alanine-mutagenesis has suggested hydrophobic,
energetic coupling between S5 and S4 helices of hERG during inactivation
involving residue I560 [24], whilst a proximate residue (H562) has been suggested
to interact with the channel pore and inﬂuence the selectivity ﬁlter [25]. It is thus
possible that eﬀects of the SQT1 I560T mutation are not restricted to the voltage-
dependence of IhERG inactivation. The present study was undertaken to provide a
detailed characterisation of the eﬀects of the I560T mutation on IhERG kinetics, on
the current’s proﬁle during physiological (AP) waveforms and on sensitivity of
the channel to the antiarrhythmic drug quinidine. In addition, the recent availability
of a hERG structure [26], obtained from cryo-electron microscopy (cryo-EM),
enabled this study to consider the functional consequences of the I560T mutation
in the context of the hERG channel structure.on.2019.e01429
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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2.1. Mutagenesis
The I560T hERG mutation was generated by PCR-based substitution by Mutagenex
Inc (Suwanee, GA 30024, USA) from a wild-type (WT) construct in modiﬁed
pcDNA3. Competent DH5a Escherichia coli (Invitrogen, Paisley, UK) were trans-
formed using standard procedures, DNA was puriﬁed by Endotoxin-free plasmid
DNA puriﬁcation kit (Neumann-Neander-Str., Germany, Macherey-Nagel), the mu-
tation was conﬁrmed by sequencing of the entire open reading frame (Euroﬁns
MWG Operon, Ebersberg, Germany).2.2. Cell culture and transfection
Human embryonic kidney (HEK 293) cells with no native IhERG (European Collection
of Cell Cultures, Porton Down, UK) were used to study the eﬀects of the I560T muta-
tion on IhERG kinetics and the current’s response to AP waveforms. These cells were
maintained at 37 C, 5% CO2 in Dulbecco’s minimum essential medium with
Glutamax-1 (DMEM; Gibco, Paisley, UK). This was supplemented with 10% fetal
bovine serum, 50 mg ml1 gentamycin (Gibco, Paisley, UK). Cells were transiently
transfected with 1mg cDNA plasmids encoding WT or mutant hERG using Lipofect-
amine 2000 (Invitrogen, Paisley, UK) according to the manufacturer’s instructions.
Due to the increased macroscopic IhERG seen in cells expressing mutant channels,
only 0.15mg cDNA plasmid encoding I560T was added for protocols in which IhERG
inactivation was measured: this prevented excessively large currents from forming
and facilitated accurate recordings. Expression plasmid encoding CD8 (0.15mg) was
also added (in pIRES, donated by Dr I Baro, University of Nantes, France) to be
used as a successful marker of transfection [27, 28]. Electrophysiological recording ex-
periments were performed 12e48 h after transfection (a range within that of prior
studies from our laboratory [28, 29]). Successfully transfected cells (positive to
CD8) were identiﬁed using Dynabeads (Invitrogen, Paisley, UK; e.g. [27, 28, 30]).
HEK 293 cells transiently transfected with I560T hERG were also used in the study
of the channel’s sensitivity to antiarrhythmic drugs. However HEK 293 cells stably
expressing WT hERG (generously donated by Dr Craig January, University of Wis-
consin, that have been used in multiple prior pharmacological studies from our lab-
oratory (e.g. [31, 32, 33]) were used for comparison of drug block with I560T under
conventional voltage clamp (cf [28, 29]), as comparison of absolute ‘control’ current
magnitudes was not required between WT and mutant conditions in those experi-
ments, with each cell providing its own control IhERG magnitude prior to drug appli-
cation (Fig. 6A,B; in contrast with Figs. 1C and 5). These cells were passaged using
enzyme free cell dissociation solution (Millipore, Watford, UK) and plated onto ster-
ilized 13-mm glass coverslips in 40-mm Petri dishes containing a modiﬁcation ofon.2019.e01429
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
Fig. 1. Current-voltage (I-V) relations forWT and I560T hERG and time-course of IhERG activation. (A, B)
Representative current traces for WT (A; blue) and I560T (B; red) IhERG elicited by the voltage protocol
shown as insets. Test pulses were applied at 10 mV increments between 40 mV and þ60 mV, with
only selected traces being shown for clarity and corresponding test potentials are indicated next to relevant
current records. (C)Mean I-V relations for end pulseWT and I560T IhERG. ** denotes signiﬁcant diﬀerence
from control at p< 0.01,whilst **** denotes signiﬁcance at p< 0.0001. (D)Mean normalized tail current I-
V relations. Currents were normalized to the peak current recorded during the protocol for each cell, and
ﬁtted by Eq. 1. (E) Activation time course of WT and I560T IhERG at þ20 mV elicited using an envelope
of tails protocol (inset), ﬁt with Eq. (2). Replicate numbers are given in each panel.
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UK). This was supplemented with 10% fetal bovine serum, 50 mg/mL gentamycin
(Gibco), and 400 mg/mL geneticin (G418, Gibco). The cells were incubated at 37
C (5% CO2) for a minimum of 1 day before any electrophysiological study [30].2.3. Solutions for electrophysiological recordings
Once in the recording chamber, cells were superfused with normal Tyrode’s contain-
ing (in mM): 140 NaCl, 4 KCl, 2.5 CaCl2, 1 MgCl2, 10 Glucose, and 5 HEPESon.2019.e01429
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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2.5e4 MU. The pipette dialysis solution for hERG current (IhERG) measurement
contained (in mM): 130 KCl, 1 MgCl2, 5 EGTA, 5 MgATP, and 10 HEPES (titrated
to pH of 7.2 with KOH) [15, 18, 28]. Quinidine powder (Quinidine gluconate salt;
Sigma-Aldrich, Gillingham, UK) was dissolved in Milli-Q water to produce an
initial stock solution of 10 mM, which was serially diluted to produce stock solutions
ranging from 10 mM to 1mM.2.4. Experimental protocols and analysis
Measurements of hERG current (IhERG) were made at 37 C 1 C as described pre-
viously [15, 18, 28, 33]. Whole-cell patch clamp recordings of membrane currents
were made using an Axopatch 200A ampliﬁer (Axon Instruments, Foster City,
CA, USA) and a CV201 head stage. Between 70% and 80% of the electrode series
resistance could be compensated. Data were recorded via a Digidata 1440A interface
(Molecular Devices, Sunnyvale, CA, USA); a bandwidth of 2e10 kHz was set on
the recording ampliﬁer and digitization rates up to 25 kHz were used. Data were
analyzed using Clampﬁt 10.2 (Axon Instruments), Excel 2016 (Microsoft, Red-
mond, WA), Origin 2017 (OriginLab Corporation, Northampton, MA, USA), and
Prism 7 (Graphpad Inc, La Jolla, CA, USA) software.
The speciﬁc voltage protocols used experimentally are detailed within the relevant
ﬁgures and associated Results. All action potential (AP) waveforms used here for
AP voltage clamp (‘AP clamp’) experiments have been used in prior studies and cur-
rents elicited under AP clamp were corrected online for P/N leak subtraction using
an interspersed P/4 protocol [28, 30, 34, 35]. Charge carried by WT and mutant
hERG channels during AP commands was determined by integrating currents using
Origin 2017.
Half-maximal activation (V0.5) voltages were obtained by normalizing IhERG tail cur-
rent values (I), following diﬀering voltage commands, to the maximal IhERG tail
value observed during the voltage protocol (Imax), plotting the resulting values
against corresponding command voltage (Vm), and ﬁtting the data with a Boltzmann
equation of the form:
I¼ Imax=ð1þ expððV0:5 VmÞ=kÞÞ ð1Þ
where k is the slope factor describing IhERG activation.
The rate of IhERG activation derived from application of an envelope of tails protocol
was obtained by ﬁtting the plotted data with an exponential equation of the form:
I¼ Imaxð1 expðK xÞÞ ð2Þon.2019.e01429
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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after which tail current amplitude was measured. Values of I were normalized to
maximal current Imax obtained during the protocol. K is the rate constant of activa-
tion, from which the time constant was derived as 1/K.
Half maximal inactivation voltage (V0.5) was obtained from normalized plots of
voltage-dependent availability, using the following equation:
1 ð1=ð1þ exp½ðV0:5 VmÞ=kÞÞ ð3Þ
Where Vm represents the repolarization voltage used to inﬂuence IhERG availability
(Fig. 2, Results) and k is the slope factor describing IhERG inactivation.
As previously [28], the IhERG window was obtained from derived activation and
inactivation V0.5 and k values by using equation (3) and a modiﬁed version of
Eq. (1) to calculate activation/inactivation variables at 2 mV intervals and then the
product of the two relations plotted to ascertain the IhERG window.
The deactivation rate of IhERG was quantiﬁed by ﬁtting tail currents with the
following bi-exponential equation:
I¼ Af exp
 xtf
þAs expð  x=tsÞ þC ð4Þ
where I represents the current amplitude at time x; Af and As represent the total cur-
rent ﬁtted by the fast and slow components of the deactivation time-course (tf and
ts respectively) and C represents any residual unﬁtted current.
Fractional inhibition of IhERG by quinidine was calculated by:
Fractional inhibition ¼ 1 ðIhERG½Drug=IhERG½ControlÞ ð5Þ
where IhERG[Drug] and IhERG[Control] represent “tail” current amplitudes in the
presence and absence of pharmacological agents respectively.
Concentration response relations were ﬁtted by a standard Hill equation of the form:
Fractional inhibition ¼ 1
.
1þ ðIC50=½DrugÞh

ð6Þ
where IC50 is [Drug] producing half-maximal inhibition of the IhERG tail and h is
the Hill coeﬃcient for the ﬁt.
Unless stated otherwise in the “Results” text, all data are presented as the mean 
standard error of the mean (SEM). Statistical comparisons were made, as appro-
priate, using a Student’s t-test (where appropriate with Welch’s correction),
Mann-Whitney U test or one- or two-way analysis of variance (ANOVA) followed
by a Bonferroni post-hoc test. P values of less than 0.05 were taken as being statis-
tically signiﬁcant.on.2019.e01429
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
Fig. 2. Inactivation properties of WT and I560T IhERG. (A) Voltage protocols used to determine IhERG
inactivation. The highlighted section is that magniﬁed in lower panels of B and C. (B, C) Representative
traces for WT (B) and I560T (C) IhERG aligned with section of protocol shown below. Brief (2 ms) re-
polarising steps to potentials between -140 mV to þ50 mV were used to elicit current, with only selected
traces shown here for clarity. Preceding repolarisation step is indicated for each trace. (D) The voltage
dependence of inactivation (availability). Currents were normalized to the peak current recorded during
the protocol for each cell and ﬁtted with Eq. (3). For currents at the most negative voltages, deactivation
correction was performed as described previously [15, 28]. V0.5 and k values are given in the Results text.
Signiﬁcant diﬀerence from control at p < 0.05, p < 0.001 and p < 0.0001 are represented by *, *** and
**** respectively. (E) Time-course for the recovery from inactivation for WT and I560T hERG, calcu-
lated from 40 mV currents elicited in 2 ms steps up to 20 ms. Recovery time constants are given in the
Results text. Replicate numbers are given in each panel.
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Similar to very recent work from our laboratory [36], computational modelling was
conducted using the recent cryo-EM open pore structure of hERG [PDB: 5VA1]
[26]. A homology model of a hERG closed pore state was also built onto the rat
EAG (rEAG) closed pore cryoEM structure [PDB: 5K7L] [37] using Modelleron.2019.e01429
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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nates of the rEAG-based closed state hERG model are available on request. Struc-
tural ﬁgures were made using PyMOL version 1.4 (Schroedinger, LLC, New
York, NY).3. Results
3.1. Eﬀects of the I560T mutation on the IhERG current-voltage
relation and voltage dependence of activation
The insets to Fig. 1A and B show the voltage protocol used to elicit IhERG, which was
similar to that applied in prior hERG channel studies from our laboratory (e.g. [15,
28]). From a holding potential of -80 mV, 2s duration depolarising test commands
were applied in 10 mV increments to potentials of -40 mV and more positive, fol-
lowed by a repolarisation step to -40 mV in order to observe IhERG tails [15, 28].
Fig. 1A shows typical records of WT IhERG elicited by this protocol. Pulse currents
increased with the magnitude of the test command up tow0 mV and declined at pos-
itive voltages; accordingly the I-V relation for WT IhERG showed a region of pro-
nounced negative slope at positive test potentials (Fig. 1C). Moreover, resurgent
IhERG tails were visible (Fig. 1A). With the same protocol, I560T IhERG during the
command pulses increased up to wþ20 mV, was larger in magnitude than that
for WT IhERG and was followed by tail current that was smaller in magnitude than
that during the preceding depolarising command pulse (Fig. 1B). Rectiﬁcation
was evident at more positive voltages for I560T IhERG than for the WT channel cur-
rent (Fig. 1B, C) and comparison of the end-pulse I-V relations for WT and I560T
(Fig. 1C) showed the current for the mutant to be signiﬁcantly greater than that for
the WT channel over most of the tested voltage range. Fig. 1D shows normalized
current-voltage plots for IhERG tails, which were ﬁtted by Eq. (1) to obtain parameters
for voltage dependent activation of the two channels. The derived half maximal acti-
vation voltage (V0.5) for WT and I560T IhERG were respectively -21.07  1.29 mV
(n ¼ 8) and -21.43  1.41 mV (n ¼ 17; p > 0.05), although there was a signiﬁcant
diﬀerence in the slope (k) of the ﬁtted activation relation (6.61  0.15 mV for WT
versus 12.55 2.14 mV for I560T; p< 0.01). In summary, application of a standard
I-V protocol to WT and I560T IhERG showed an increase in current density with the
I560T mutation, with no signiﬁcant alteration to voltage dependent activation of the
channel.
The presence of overlapping activation and rapid inactivation during depolarisation
to positive membrane potentials makes it diﬃcult to quantify the time-dependence of
IhERG activation during depolarising commands and, instead, an “envelope of tails”
protocol is typically used (e.g. [6, 32]). The inset to Fig. 1E shows the envelope ofon.2019.e01429
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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Tail currents elicited following the diﬀerent duration voltage commands were
normalized to the maximal tail current obtained during the protocol and then the re-
sulting mean data plotted against pulse duration as shown in Fig. 1E and ﬁtted with
Eq. (2) (Methods)). The mean time-constant of IhERG activation in WT conditions
was 65.4  3.5 ms (n ¼ 5) and that for I560T was 19.6  1.7 ms (n ¼ 7;
p < 0.0001). Thus, in the presence of the I560T mutation, IhERG activation was
accelerated.3.2. Eﬀects of the I560T mutation on inactivation properties of
IhERG
The voltage-dependence of inactivation of IhERG was determined in WT and mutant
conditions using the protocol shown in Fig. 2 [15, 28]. After an initial depolarising
command toþ40 mV to activate and inactivate IhERG, brief (2 ms) repolarising com-
mands to a range of membrane potentials (in 10 mV increments down to -140 mV)
were used to alleviate IhERG inactivation to diﬀering extents and then the amplitude
of the rapid IhERG transient during the third step (toþ40 mV) was measured. Fig. 2B
and C show for WT and I560T conditions expanded portions of the resulting current
records, highlighting the rapid IhERG transients elicited by the third step, whilst
Fig. 2D show mean normalised plots of IhERG availability (with the amplitudes of
currents during the third step normalised to the maximal current obtained, and
then plotted against repolarisation potential, as described previously [15, 28]). The
data in Fig. 2D were then ﬁtted with Eq. (3), to obtain inactivation V0.5 and k values.
For cells expressing the WT channel, IhERG inactivation was typically half-maximal
between -60 and -70 mV (mean V0.5 of -66.25 1.91 mV and k¼ 20.15 0.62 mV,
n ¼ 6), whilst for I560T hERG, inactivation was positively shifted (mean V0.5 of
-41.79  3.47 mV and k ¼ 25.31  1.22 mV, n ¼ 13; p < 0.001 and p < 0.01
respectively versus WT for both). Thus, voltage dependent inactivation of IhERG
was positively shifted by wþ24.5 mV for I560T IhERG. It is also evident from
the current traces in Fig. 2B,C that the rate of development of inactivation was
slower for I560T than WT IhERG and this was quantiﬁed by monoexponential ﬁtting
of the decline of IhERG transients following repolarisation steps to -120mV. For WT
IhERG, the mean inactivation time-constant was 2.31  0.17 ms (n ¼ 6), whereas for
I560T IhERG it was 4.72 0.36 ms (n¼ 13; p< 0.01). In contrast, the time-course of
recovery of inactivation (obtained using the protocol shown in the inset of Fig. 2E
[34]) did not diﬀer signiﬁcantly between WT and I560T IhERG, with recovery
time-constants respectively of 1.84  0.08 ms (n ¼ 10) and 2.05  0.17 ms (n ¼
18; p > 0.05).on.2019.e01429
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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relation and the IhERG “window”
The fully activated I-V relation for IhERG was elicited by the protocol shown in the
insets to Fig. 3A and B [15,28]. From a holding potential of -80 mV, the membrane
potential was stepped to þ40 mV for 500 ms, after which voltage commands were
applied for 5 seconds at 10 mV steps between -100 mV andþ40 mV. As can be seen
in the representative traces of Fig. 3A and B, WT tail current peaks rose as expected
[15, 28] as the membrane potential became less negative; these peaked at -20 mV,
with I560T IhERG following a similar pattern, albeit with a slightly more positive
peak at -10 mV (Fig. 3F). By ﬁtting the tail current decline at each repolarisationFig. 3. Fully activated I-V relations and the IhERG ‘window’. (A, B) Representative traces for WT
(A; Blue) and I560T (B; Red) elicited by the protocol shown in insets with only selected sweeps shown
for clarity. (C, D) Fast (tf) and slow (ts) time constants of deactivation calculated using Eq. (4). Signif-
icant diﬀerence from control at p < 0.05, p < 0.01 and p < 0.001 are represented by *, ** and ***
respectively. (E) Plots of the fraction (Af/Af þ As) of fast deactivating current (ﬁtted by the tf) against
voltage, from same experiments as C,D. (F) Fully activated I-V relations, calculated with currents
normalized to the peak current recorded during the protocol for each cell.
on.2019.e01429
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deactivation were obtained. As can be seen in Fig. 3C and D, tf and ts were
modestly increased for I560T IhERG compared to WT hERG at some voltages.
This indicates a slight, but signiﬁcant decrease in the rate of deactivation for the
mutant channel. It is notable that neither tf nor ts was signiﬁcantly altered at -80
or -90 mV (i.e. close to the likely resting potential of ventricular myocytes) and
so it is unlikely that IhERG deactivation would be signiﬁcantly slowed by the
I560T mutation during diastole. The relative proportions of fast and slow deactivat-
ing IhERG were unaltered by the I560T mutation (Fig. 3E). This voltage protocol also
revealed a modest but statistically signiﬁcant positive shift in the reversal potential
(Erev) of IhERG: for WT IhERG Erev was -85.05  0.53 mV (n ¼ 5), whilst that for
I560T was -80.34  1.4 mV (n ¼ 11; p < 0.001; Fig. 3F). Using a modiﬁed
Goldman-Hodgkin-Katz equation, the relative Naþ:Kþ permeability ratio was found
to change from a WT hERG value of 0.010 to 0.016 for the mutant channel, indi-
cating a modest decrease in the mutant channel’s selectivity for Kþ over Naþ ions
(cf [15]).
Fig. 4 shows the eﬀects of the I560T mutation on the steady-state IhERG window.
Window current was calculated as described in the Methods and plots of steady state
activation and inactivation parameters were calculated at 2 mV intervals and areFig. 4. IhERG window current. (A, B) Superimposed activation and inactivation (availability) curves for
WT (blue) and I560T (red) IhERG respectively. Activation and inactivation parameters were calculated at
2 mV intervals, using the V0.5 and k values obtained from ﬁtting experimental data. (C) Product of acti-
vation and inactivation parameters plotted against voltage to show steady state WT and I560T IhERG
window.
on.2019.e01429
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tion parameters at each voltage was plotted as shown in Fig. 4B to give the IhERG
window current (cf [28]). The IhERG window was substantially larger for I560T
IhERG than for WT IhERG.3.4. Eﬀects of the I560T mutation under action potential clamp
Fig. 5 compares WT and I560T IhERG under action potential (AP) voltage clamp,
during ventricular, atrial and Purkinje ﬁbre AP voltage commands. Fig. 5Ai shows
overlays of WT and I560T IhERG superimposed on a ventricular AP command (as
used previously in [28, 34]), showing augmented current for I560T IhERG during
the entire repolarising phase of the AP. Fig. 5Aii shows plots of the normalised
instantaneous I-V relations for WT and I560T IhERG, showing that maximal IhERG
occurred at -29.7  2.7 mV for WT hERG (n ¼ 5) and at -11.9  3.4 mV (n ¼
19; p < 0.05) for I560T hERG. Fig. 5D compares current integrals for WT and
I560T IhERG, showing that the total charge carried during the ventricular AP com-
mand wasw2.6 fold greater for I560T than for WT hERG (p< 0.01). Fig. 5B shows
similar data during an imposed atrial AP voltage command (as used previously in
[27]). Fig. 5Bi shows that, similar to the situation with the ventricular AP command,
IhERG was augmented throughout AP repolarisation in the I560T condition, corre-
sponding to a w2.3 fold increase in charge in Fig. 5D (p < 0.001). However, the
lower AP plateau phase of the atrial AP was associated with less extensive activation
of IhERG (evident in the smaller current integrals for the atrial than ventricular AP in
Fig. 5D) and the voltage at which maximal IhERG occurred during repolarisation was
not signiﬁcantly diﬀerent betweenWT and I560T conditions (Fig. 5Bii;24.0 2.5
mV (n ¼ 15) and -24.4  2.3 mV (n ¼ 16) for WT and I560T respectively (p >
0.05)). Fig. 5C shows similar data for a Purkinje ﬁbre command (as used in [40]).
Again, IhERG was augmented for I560T compared to WT IhERG (Fig. 5Ci) with a
w2.2 fold increase in charge carried during AP repolarisation (Fig. 5D). Similar
to the situation with the ventricular AP command, maximal IhERG occurred earlier
during the AP with the I560T mutation, reﬂected in a more positive voltage at which
maximal current occurred (-17.5  3.5 mV for I560T (n ¼ 7) compared to -35.1 
0.8 mV for WT (n ¼ 7; p < 0.01)). In summary, the I560T mutation resulted in
increased IhERG during all three AP command waveforms, with current also peaking
earlier during ventricular, Purkinje ﬁbre, but not atrial AP commands.3.5. Sensitivity of I560T hERG to quinidine
(Hydro)quinidine has been used successfully in the treatment of congenital SQTS
[11, 41, 42, 43], with relatively modest eﬀects on its hERG blocking potency re-
ported for the N588K and T618I hERG mutations [16, 17, 19, 20]. In order to estab-
lish quinidine’s eﬀectiveness against I560T IhERG the voltage protocol shown in theon.2019.e01429
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
Fig. 5. WT and I560T IhERG response to action potential voltage clamp (AP clamp). (A) Mean IhERG
proﬁle from 19 I560T (red) and 5 WT (blue) AP clamp experiments (Ai) and corresponding instanta-
neous I-V relations (Aii) during ventricular AP. (B) Mean IhERG proﬁle from 16 I560T (red) and 15
WT (blue) AP clamp experiments (Bi) and corresponding I-V relations (Bii) during atrial AP. (C)
Mean IhERG proﬁle from 7 WT (blue) and 7 I560T (red) AP clamp experiments (Ci) and corresponding
instantaneous I-V relations (Cii) during Purkinje ﬁbre AP. For all I-V relations, for each cell currents
from 5 ms onwards following the initial AP upstroke were normalized to the peak current recorded dur-
ing the repolarising phase of the AP and mean values plotted. (D) Comparison of the total charge con-
ducted during each action potential, calculated by integrating the current traces, normalized to cell
capacitance. Statistically signiﬁcant diﬀerences at p < 0.05 and p < 0.01 are represented by * and **
respectively.
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Fig. 6. Response of WT and I560T IhERG to quinidine. (Ai, Aii) Representative traces of WT (blue) and
I560T (red) IhERG respectively, elicited by the protocol shown as the lower traces in each panel and re-
corded in the absence (black) or presence (grey) of 1 mM quinidine. The interval between successive ap-
plications of the protocol was 12 s. (B) Concentration-response relations for inhibition of WT and I560T
IhERG. Fractional inhibition of IhERG by the range of concentrations shown was calculated using Eq. (5),
with a minimum of 5 cells used for each concentration of drug. IC50 and Hill coeﬃcient values were
calculated using Eq. (6) and are given in the Results. (Ci,Cii) Eﬀects of 1 mM quinidine on IhERG elicited
under AP clamp for WT IhERG (Ci; blue) and I560T (Cii; red). AP commands were applied at 1 Hz. (D)
Bar chart comparing extent of quinidine inhibition of maximal IhERG during repolarisation (n ¼ 7 for WT
and 6 for I560T IhERG). (E) Bar chart comparing eﬀect of quinidine on voltage at which peak IhERG
occurred during AP repolarisation, expressed as the mV shift in peak current, for WT (n ¼ 7) and
I560T (n ¼ 6) IhERG. (* denotes statistical signiﬁcance at p < 0.05).
15 https://doi.org/10.1016/j.heliyon.2019.e01429
2405-8440/ 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Article Nowe01429
16 https://doi.org/10.1016/j.heliy
2405-8440/ 2019 The Auth
(http://creativecommons.org/li
Article Nowe01429insets to Fig. 6Ai and Aii was used. This protocol has been employed in multiple
prior studies of IhERG pharmacology from our laboratory (e.g. [17, 28, 29]).
Fig. 6Ai, Aii show the eﬀects of 1 mM quinidine on WT and I560T IhERG respec-
tively. In both conditions, quinidine produced substantial IhERG inhibition. Frac-
tional inhibition of IhERG ‘tails’ at -40 mV was calculated by measuring tail
current magnitude in control and drug relative to the brief (50 ms) prepulse to -40
mV (as in [17, 28, 29]) and applying Eq. (5). Mean fractional block data at ﬁve con-
centrations were then plotted as shown in Fig. 6B and ﬁtted with Eq. (6) to obtain
half-maximal inhibition (IC50) and Hill coeﬃcient (h) values. For WT IhERG, the
derived IC50 was 0.38  0.03 mM with an h value of 0.86  0.06. For I560T, an
IC50 value of 0.88  0.14 mM (2.3-fold the WT value; p < 0.01) with an h value
of 0.70  0.09. The IhERG blocking potency of some drugs is sensitive to the stim-
ulus protocol used to activate IhERG [44, 45]. Therefore, additional experiments were
performed in which 1 mM quinidine was applied under ventricular AP clamp. As
shown in Fig. 6Ci and Cii, the amplitude of IhERG elicited by the ventricular AP com-
mand was substantially reduced by quinidine for both WT and I560T IhERG. The bar
charts in Fig. 6D show mean (SEM) inhibition of peak IhERG during the ventricular
AP command; this was only modestly reduced for I560T compared toWT IhERG. We
also quantiﬁed the reduction in net charge carried by IhERG throughout the AP com-
mand (cf [46]), which 1 mM quinidine reduced by 78.5  4.8% (n ¼ 7) for WT
hERG and 68.6  3.0% (n ¼ 6) for I560T hERG (p > 0.05 vs WT). Thus, in
both conventional voltage clamp and AP clamp experiments, I560T hERG largely
retained sensitivity to quinidine. In addition, under AP clamp the voltage at which
peak IhERG occurred during AP repolarisation was shifted to more negative poten-
tials for I560T IhERG, whilst that for WT IhERG was unaﬀected (Fig. 6E).3.6. Location of I560 in the hERG channel structure
Our experimental data indicate that the I560T mutation produces multiple eﬀects on
hERG channel kinetics: accelerating activation, slowing inactivation and positively
shifting the voltage dependence of inactivation, whilst also modifying ion selectivity
of the channel. Prior work has suggested hydrophobic, energetic coupling between
S5 and S4 helices of hERG during inactivation involving residue I560 [24]. A struc-
ture of the open hERG channel has recently been reported using cryo-electron mi-
croscopy (cryo-EM) [26], whilst a closed-pore state of the closely related EAG
channel has also been captured [37]. We have recently constructed a closed channel
model of hERG based on the related rEAG structure [36, 37]. Fig. 7 shows the loca-
tion of the I560 residue in open and closed hERG channel conformations. Fig. 7A
shows I560 on the S5 helix in the context of the full membrane domain along
with the location of other residues that attenuate hERG inactivation. Expanded re-
gions around the centre of the S5 helix in the hERG structure and the rEAG-
based hERG model are shown in Fig. 7B and C, respectively, along with atomson.2019.e01429
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
Fig. 7. Structural context of the I560 residue. (A) Membrane domain of the recent hERG construct cryo-
EM structure [26] highlighting I560 and other selected inactivation-attenuating residues. VS: voltage
sensor; SF: selectivity ﬁlter. The three subunits that are not highlighted/annotated are coloured pale
blue. (B) Close up of the S5 helix containing I560 with all atoms within 7 A of any I560 side chain
atom shown as sticks coloured according to their origin (e.g. the side chain of L622 on the pore helix
is within 7 A and is coloured grey). I560 makes no interactions with residues on the voltage sensor
domain including S4. (C) A similar conclusion arises from inspection of a hERG homology model built
on the cryo-EM structure of EAG [37]. Amino acid annotations are residues on S5 near I560 that do
potentially interact (C-C distances within 5 A) with residues on S1 (L559; W563), the pore helix
(A561; L564) and S6 (F557).
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and rEAG-based model I560 is oriented towards the membrane bilayer and makes no
direct interactions with residues in other protein domains apart from an interaction
with the long side chain of M651 on S6 (Fig. 7B,C; this is the only remaining close
approach if the distance constraint is reduced from 7A to 5A). We were not able to
substantiate prior interpretations from homology modelling based on the structure of
Kv1.2/2.1 chimeric channels [24] that I560 is proximate to hydrophobic residues on
the S4 domain of an adjacent subunit in the tetramer. If present, such interactions
would have been identiﬁed by light blue atom stick representations in Fig. 7B and
C. The absence of interdomain S5-S4 interactions is a consequence of the non-
domain-swapped arrangement of subunits in the hERG (and EAG) structure, but
the new cryoEM structures also demonstrate that direct intrasubunit interactions be-
tween I560 on S5 and S4 residues do not occur at least in the membrane-depolarized
states captured in the cryoEM structures. The most intimate interactions with the S5
helix involve close packing between S5 and the pore helix where the side chains
methyl groups of A561 (adjacent to I560) and A565 slot between the side chains
on the pore helix (Fig. 8), which is noteworthy given the role of pore helix residues
in IhERG inactivation and the proximity of this region to the selectivity ﬁlter (Fig. 8).
In summary, consideration of the I560T mutant in the context of available informa-
tion on hERG channel structure indicates that I560 appears to face membrane lipidon.2019.e01429
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
Fig. 8. Helix-helix interactions potentially relevant to hERG gating. Hydrophobic side chains on the
voltage sensor S4 helix interact closely with sides chains on S1 (A422, V418, L415 indicated by asterisks
for clarity) but not with S5. S1 interacts with the pore domain via a cluster of aromatic amino acids
involving S1 (F431), S5 (Y569) and the pore helix (PH; Y611 hidden from view). S5 interacts with
the pore helix via side chain “knobs into holes” packing involving A561 and A565 on S5 (green spheres
with yellow hydrogens) and A614, L615, T618 and F619 side chains on the pore helix. The S5-pore he-
lix interface is immediately adjacent to the selectivity ﬁlter (SF). hERG mutations that perturb inactiva-
tion gating are indicated with mutation in parentheses. Hydrogens have been omitted from side chains
highlighted in the voltage sensor for clarity.
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helix, but has the potential to inﬂuence interactions between S5 and the pore helix.4. Discussion
4.1. Eﬀects of the I560T mutation on IhERG in context
The results of this study indicate that the eﬀects of the I560T mutation on IhERG are
more extensive than those reported when this mutation was ﬁrst implicated in the
SQTS [12]. Our results accord well with those of Harrell and colleagues in respect
of increased IhERG magnitude and lack of alteration to half-maximal activation
voltage of IhERG with the mutation. Harrell and colleagues did not comment on
any eﬀect of I560T on the slope factor for IhERG activation, however, whilst we
observed a modest though statistically signiﬁcant diﬀerence between WT and
I560T k values, with more variability in this parameter for the mutant than WT chan-
nel (as shown by the respective SEM values). The positive shift in voltage-
dependent inactivation seen in the present study (þ24 mV) is larger than that re-
ported in the initial report of the mutation (þ14 mV) [12] and is comparable to those
produced by the L532P (þ32 mV) [28] and T618I (þ25 mV) [20] mutations thaton.2019.e01429
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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however, that the WT inactivation V0.5 value for IhERG from the study by Harrell
and colleagues was relatively positive (-27.3 mV) in comparison with that in the pre-
sent and other studies [14, 15, 28, 47], which might have led to an underestimation of
the diﬀerences between WT and I560T IhERG in [12]. The reasons for the diﬀerences
between the two studies in this regard are not known: both were conducted at phys-
iological temperature, but diﬀerences in expression system (HEK 293 versus COS-
7) and voltage protocol may have contributed. Alterations to other kinetics parame-
ters (activation/deactivation rates, inactivation rate) and ion selectivity seen here for
the I560T mutation have not previously reported [12] and demonstrate an inﬂuence
of the I560T substitution on multiple properties of the hERG channel.
The I560 residue in ERG is well-conserved across species [12] and has been previ-
ously linked to inactivation gating of hERG via putative hydrophobic interactions
with the voltage sensor S4 helix [24] (dark blue in Figs. 7 and 8). Leucine and valine
residues on the S4 helix (L529, L530, L532 and V535) have been proposed to be key
molecular determinants of inactivation gating [24]. Rate equilibrium free energy
relationship (REFER) analysis has led to the proposition that conformational rear-
rangements of the S5 helix and S5-Pore linker precede that for S4, which in turn oc-
curs before that for S6. Double mutant cycle analysis combining each of L529S,
L530S, L532S and V535S with the I560A mutation showed their eﬀects to be
non-additive, leading to the conclusion of energetic coupling between S4 and S5 res-
idues [24]. In a hERG homology model based on the Kv1.2/2.1 crystal structure, hy-
drophobic residues on S4 and S5 of adjacent subunits faced one another, leading to a
conclusion that energetic coupling is likely to occur via hydrophobic interactions
[24]. A surprising conclusion from the present study is that if the I560 residue is
examined in the context of the cryoEM hERG structure [26], it does not face an adja-
cent S4 domain in the gated state; this is also the case for a closed channel model
built on rEAG (Fig. 7). In fact the S5 helix does not make any interactions with
S4 in the cryoEM structures of hERG and EAG (Figs. 7 and 8).
An alternative explanation for the gating eﬀects of the I560T mutation is threonine-
induced bending of the S5 helix [48]: the polar hydroxyl side chains of threonine and
serine interact poorly with lipid chains and may preferentially hydrogen-bond with
the backbone carbonyl oxygen of amino acids three or four residues towards the N-
terminus in helices (T556 and F557 in the case of I560T in hERG) as commonly
found in transmembrane helices of membrane proteins (e.g. [48, 49, 50]). This inter-
action induces a small bend in the helix that would be expected to perturb S5 inter-
actions in I560T hERG. The most intimate interactions with the S5 helix involve
close packing between S5 and the pore helix where the side chains methyl groups
of A561 (adjacent to I560) and A565 slot between side chains on the pore helix
(Fig. 8). Minor disruption of this interface by mutation at I560 is likely to inﬂuenceon.2019.e01429
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
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mental role in the dynamics of hERG inactivation [51].
In fact, inspection of the hERG cryoEM structure suggests a common theme in the
transmission of eﬀects of inactivation-perturbing mutations in the S4, S5 and pore
helices to the selectivity ﬁlter. Rather than direct interactions with S5 as previously
suggested [24], the S4 helix residues L529, L532 and V535 interact directly with res-
idues on the voltage sensor S1 helix, at least in the voltage sensor activated state
(Fig. 8). Eﬀects of mutation on S4 are therefore expected to be transmitted to the
selectivity ﬁlter via the S1 helix most likely through a cluster of aromatic amino
acids (F431 on S1, Y569 on S5 and Y611 on the pore helix) that interact closely
at the extracellular ends of the S1, S5 and pore helices (Fig. 8). We previously
showed that the inactivation-perturbing mutation L532P [28] perturbs the conforma-
tion of the S4 helix [52] and this should aﬀect the S4-S1 helix interactions. Thus each
of the inactivation-perturbing mutations L532P, I560T, T618A/I lie within a
network of helix interactions involving S4-S1, S1-S5 and S5-PH (Fig. 8) and trans-
mission of gating eﬀects from the voltage sensor to the selectivity ﬁlter is likely to
involve these interactions rather than direct S4-S5 helix interactions. Previously, the
N588K SQT1 mutation in the S5-Pore linker (which is spatially distinct from the
pore) has been seen not only to disrupt inactivation gating, but also to produce
modest change in pNa:pK ratio [15]. By analogy, eﬀects of changes to S5 on inter-
actions with the pore helix, or mediated via the S5-Pore linker, could inﬂuence ion
selectivity.4.2. Clinical relevance of the ﬁndings of this study
The patient in whom the I560T mutation was initially identiﬁed presented with atrial
ﬁbrillation and ﬂutter, and his short QTc interval became evident following catheter
ablation treatment for supraventricular arrhythmia. Thus the presenting arrhythmias
were supraventricular, although the patient’s father and brother had undergone sud-
den death [12]. Simulations performed to probe the consequences of the changes to
IKr due to the I560T mutation reproduced abbreviation of ventricular repolarisation
and showed increased susceptibility to ventricular ﬁbrillation, which is consistent
with sudden death reported in the patient’s family. Simulations were not included
to investigate eﬀects of the mutation on atrial electrophysiology [12]. The ﬁndings
of our study indicate that more extensive alterations to in silico representations of
IhERG/IKr are likely to be required to recapitulate accurately in silico the mutant’s ef-
fects at the channel level and consequently upon cell/tissue simulations. Moreover,
our AP clamp data both provide clear evidence that the I560T mutation can accel-
erate repolarisation of ventricular and supraventricular APs and provide a resource
for accurate validation of in silico of the mutation’s eﬀects (cf [53]). Both magnitude
and timing of IKr during ventricular and Purkinje ﬁbre APs are likely to be altered byon.2019.e01429
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
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be on current magnitude. The more than doubling of IKr magnitude is highly likely to
abbreviate both the atrial AP and eﬀective refractory period (ERP), thus facilitating
re-entrant atrial arrhythmia, which is consistent with the AF and ﬂutter seen in the
index patient. Increased current magnitude and earlier timing of peak repolarising
current is anticipated to abbreviate AP duration and ERP in both ventricular and Pur-
kinje ﬁbre cells. Previously, the increase in IhERG caused by the N588K hERG SQT1
mutant was found to be greater during ventricular than Purkinje APs [14, 34], which
may contribute towards heterogeneity of repolarisation and ventricular arrhythmia
substrate. Here, the increase in net charge during ventricular and Purkinje ﬁbre
APs was 2.6 and 2.2 fold respectively. A comparative simulation approach is
required to establish whether or not the extent of the diﬀerence between the two
translates into increased heterogeneity between Purkinje ﬁbre and ventricular AP re-
polarisation in the I560T setting. Moreover, through the systematic incorporation in,
and omission from, simulations of the diﬀerent kinetic eﬀects and altered ion selec-
tivity seen here for I560T hERG, it should be possible to determine which are most
signiﬁcant for the SQTS phenotype with this mutation.
To our knowledge, drug sensitivity of the I560T hERGmutation has not been probed
previously. Long term follow-up of SQTS patients found quinidine to be more eﬀec-
tive in patients with the SQT1 variant than in non-SQT1 patients [41]. The N588K
mutation, which profoundly alters IhERG inactivation, increases the IC50 for quini-
dine inhibition of IhERG block by 3.5e5.8 fold [16, 17] and the drug retains eﬀective-
ness in patients with that mutation [41, 54]. Recent simulation data provide evidence
that the beneﬁcial eﬀects of quinidine on ventricular repolarisation in N588K-linked
SQT1 are attributable to its actions on hERG, whilst eﬀects to prolong refractoriness
also involve its Na channel actions [55]. Here, the IC50 for I560T IhERG block by
quinidine was 2.3 fold that of WT IhERG and, under AP clamp, the ability of 1
mM quinidine to reduce IhERG and the current integral during the AP was little
aﬀected by the I560T mutation. In addition, quinidine mitigated the positive shift
in voltage dependence of peak IhERG during the AP command. For the T618I
hERG SQT1 mutation quinidine has previously been suggested to shift voltage-
dependent inactivation and the “fully-activated” I-V relation towards those of WT
IhERG [19]. Similar eﬀects could potentially account for the negative shift in peak
I560T IhERG during AP repolarisation seen here with quinidine. Consistent with
this notion, the instantaneous voltage dependence of WT IhERG/IKr during ventricular
AP repolarisation is known closely to match the IhERG fully-activated I-V relation
[56] and the voltage dependence of I560T IhERG during the ventricular AP in the
presence of quinidine became closer to that of the WT channel (Fig. 6C). Plasma
levels of quinidine can readily reach micromolar levels during daily dosing regimens
[57] and considering our results in this context we would anticipate that quinidine is
likely to retain its ability to reduce IKr amplitude in I560T-linked SQT1. The fact thaton.2019.e01429
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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is likely to reﬂect the fact that they are much less dependent on hERG channel inac-
tivation to bind than are high aﬃnity drugs such as methanesulphonanilides [18, 59,
60]. The smaller attenuation of quinidine’s action by the I560T than by the N588K
mutation (which shifts inactivation by þ60 to þ90 mV [14, 15]) is also consistent
with this. The patient in whom the I560T mutation was found refused an implantable
deﬁbrillator and it is not stated as to whether or not he received antiarrhythmic drug
treatment. However, quinidine is likely to be beneﬁcial in reducing the increased
IhERG/IKr and, potentially, also in restoring the current’s timing during the ventricular
AP in this form of the SQTS.4.3. Limitations
The present study used homozygous expression of I560T hERG, to enable direct
comparison with the characteristics of IhERG with this mutation ﬁrst reported by Har-
rell et al, who used homozygous mutant expression conditions [12]. However, the
proband in whom the I560T hERG mutation was identiﬁed was heterozygous for
the mutation [12]. Whilst there is ample precedent for in vitro investigations of het-
erozygous hERG mutations in SQTS using homozygous expression conditions [8,
14, 15, 16, 17, 18, 19, 20, 46], heterozygous subunit composition may lead to quan-
titative diﬀerence in the eﬀects of the mutation to those reported here and previously
[12] using homozygous expression. For example, the use of concatemeric channels
has shown graded eﬀects of the S631A mutation on IhERG inactivation [61]: tetra-
meric channels incorporating a single S631A subunit showed a positive inactivation
V0.5 shift that was 69% of that for the homozygous tetramer, whilst incorporation of
a second S631A subunit only modestly increased this to 73% of that for the homo-
zygous channel [61]. Future work is warranted to compare consequences of hetero-
zygous and homozygous expression of the I560T mutation. In respect of the eﬀect of
the I560T mutation on quinidine block of IhERG, heterozygous expression might be
expected to result in an inhibitory potency that lies between those for WT and ho-
mozygous expression conditions (for which in any case the alteration here was rela-
tively small). Notably, predictions of retained eﬀectiveness of quinidine and
disopyramide based on homozygous expression have correlated well with patient
observations for the N588K mutation, which produces a much larger voltage shift
in inactivaction kinetics to that seen here for I560T [8, 16, 17]. So, the fact that
the I560T mutation had only a small eﬀect on quinidine potency is signiﬁcant.
In common with most investigations, this study relied on recordings from hERG1a
channels. Increasing evidence suggests that native IKr may be comprised of both
hERG1a and the shorter hERG1b isoform [62, 63]. To our knowledge, only one pre-
vious study has systematically investigated the eﬀects of any SQT1 mutation using
hERG1b; it found that the attenuation of IhERG inactivation by the N588K mutationon.2019.e01429
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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also occur for the I560T mutation merits future investigation. Similarly, whether
changes seen for hERG alone (here and previously [12]) may be inﬂuenced by
co-expression with potential accessory subunits (KCNE1/KCNE2) also remains to
be determined.5. Conclusions
The I560T mutation increases IhERG magnitude and positively shifts voltage depen-
dence of IhERG inactivation, whilst slowing the rate of development of inactivation
and accelerating activation time-course. The gain of function produced by the
mutant is anticipated to increase IKr during atrial, ventricular and Purkinje ﬁbre
APs, accelerating repolarisation and thereby abbreviating refractoriness. Whilst
our data do not preclude conformational coupling between I560 and S4 residues,
the channel structure seems inconsistent with direct hydrophobic interactions be-
tween the two. The cryoEM structures of hERG and rEAG indicated that any
such conformational coupling is likely to be indirect and mediated by interactions
amongst S1, S5, and the pore helix. The reduction in potency of quinidine block
of IhERG by the I560T mutation is suﬃciently small that the drug is likely to be of
value in limiting the increase in magnitude and altered timing of IKr in SQT1 caused
by this mutation.Declarations
Author contribution statement
Andrew Butler: Performed the experiments; Analyzed and interpreted the data;
Wrote the paper.
Yihong Zhang, Christopher E. Dempsey: Conceived and designed the experiments;
Performed the experiments; Analyzed and interpreted the data; Wrote the paper.
Jules C. Hancox, A. Graham Stuart: Conceived and designed the experiments;
Analyzed and interpreted the data; Wrote the paper.Funding statement
This work was supported by Sudden Arrhythmic Death Syndrome UK (SADS UK;
AGS and JCH) and the British Heart Foundation (JCH and CED; PG/15/106/31915
and PG/17/89/33414).on.2019.e01429
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
24 https://doi.org/10.1016/j.heliy
2405-8440/ 2019 The Auth
(http://creativecommons.org/li
Article Nowe01429Competing interest statement
The authors declare no conﬂict of interest.Additional information
No additional information is available for this paper.References
[1] J. Tamargo, R. Caballero, R. Gomez, C. Valenzuela, E. Delpon, Pharmacology
of cardiac potassium channels, Cardiovasc. Res. 62 (1) (2004) 9e33.
[2] J.M. Nerbonne, R.S. Kass, Molecular physiology of cardiac repolarization,
Physiol. Rev. 85 (4) (2005) 1205e1253.
[3] F. Charpentier, J. Merot, G. Loussouarn, I. Baro, Delayed rectiﬁer Kþ currents
and cardiac repolarization, J. Mol. Cell. Cardiol. 48 (1) (2010) 37e44.
[4] A.S. Dhamoon, J. Jalife, The inward rectiﬁer current (Ik1) controls cardiac
excitability and is involved in arrhythmogenesis, Heart Rhythm 2 (3) (2005)
316e324.
[5] M.C. Sanguinetti, C. Jiang, M.E. Curran, M.T. Keating, A mechanistic link
between an inherited and an acquired cardiac arrhythmia: HERG encodes
the IKr potassium channel, Cell 81 (1995) 299.
[6] M.C. Trudeau, J.W. Warmke, B. Ganetzky, G.A. Robertson, HERG, an in-
ward rectiﬁer in the voltage-gated potassium channel family, Science 269
(1995) 92e95.
[7] M.C. Sanguinetti, M. Tristani-Firouzi, hERG potassium channels and cardiac
arrhythmia, Nature 440 (7083) (2006) 463e469.
[8] R. Brugada, K. Hong, R. Dumaine, J. Cordeiro, F. Gaita, M. Borggrefe, et al.,
Sudden death associated with short-QT syndrome linked to mutations in
HERG, Circulation 109 (2004) 30e35.
[9] D. Hu, Y. Li, J. Zhang, R. Pfeiﬀer, M.H. Gollob, J. Healey, et al., The pheno-
typic spectrum of a mutation hotspot responsible for the short QT syndrome,
JACC Clin. Electrophysiol. 3 (7) (2017) 727e743.
[10] I. Gussak, P. Brugada, J. Brugada, R.S. Wright, S.I. Kopecky, B.R. Chaitman,
et al., Idiopathic short QT interval: a new clinical syndrome? Cardiology 94
(2000) 99e102.on.2019.e01429
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
25 https://doi.org/10.1016/j.heliy
2405-8440/ 2019 The Auth
(http://creativecommons.org/li
Article Nowe01429[11] P. Maury, F. Extramiana, P. Sbragia, C. Giustetto, R. Schimpf, A. Duparc, et
al., Short QT syndrome. Update on a recent entity, Arch. Cardiovasc. Dis. 101
(11e12) (2008) 779e786.
[12] D.T. Harrell, T. Ashihara, T. Ishikawa, I. Tominaga, A. Mazzanti,
K. Takahashi, et al., Genotype-dependent diﬀerences in age of manifestation
and arrhythmia complications in short QT syndrome, Int. J. Cardiol. 190
(2015) 393e402.
[13] K. Hong, P. Bjeerregaard, I. Gussak, R. Brugada, Short QT syndrome and
atrial ﬁbrillation caused by mutation in KCNH2, J. Cardiovasc. Electrophysiol.
16 (2005) 394e396.
[14] J.M. Cordeiro, R. Brugada, Y.S. Wu, K. Hong, R. Dumaine, Modulation of IKr
inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in
short QT syndrome, Cardiovasc. Res. 67 (2005) 498e509.
[15] M.J. McPate, R.S. Duncan, J.T. Milnes, H.J. Witchel, J.C. Hancox, The
N588K-HERG Kþ channel mutation in the ’short QT syndrome’: mechanism
of gain-in-function determined at 37oC, Biochem. Biophys. Res. Commun.
334 (2005) 441e449.
[16] C. Wolpert, R. Schimpf, C. Giustetto, C. Antzelevitch, J.M. Cordeiro,
R. Dumaine, et al., Further insights into the eﬀect of quinidine in short QT
syndrome caused by a mutation in HERG, J Cardiovasc. Electrophysiol 16
(2005) 54e58.
[17] M.J. McPate, R.S. Duncan, H.J. Witchel, J.C. Hancox, Disopyramide is an
eﬀective inhibitor of mutant HERG Kþ channels involved in variant 1 short
QT syndrome, J. Mol. Cell. Cardiol. 41 (2006) 563e566.
[18] M.J. McPate, R.S. Duncan, J.C. Hancox, H.J. Witchel, Pharmacology of the
short QT syndrome N588K-hERG Kþ channel mutation: diﬀerential impact
on selected class I and class III antiarrhythmic drugs, Br. J. Pharmacol. 155
(2008) 957e966.
[19] Y. Sun, X.Q. Quan, S. Fromme, R.H. Cox, P. Zhang, L. Zhang, et al., A novel
mutation in the KCNH2 gene associated with short QT syndrome, J. Mol.
Cell. Cardiol. 50 (3) (2011) 433e441.
[20] A. El Harchi, D. Melgari, Y.H. Zhang, H. Zhang, J.C. Hancox, Action poten-
tial clamp and pharmacology of the variant 1 short QT syndrome T618I hERG
K(þ) channel, PLoS One 7 (12) (2012), e52451.on.2019.e01429
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
26 https://doi.org/10.1016/j.heliy
2405-8440/ 2019 The Auth
(http://creativecommons.org/li
Article Nowe01429[21] C.J. Redpath, M.S. Green, D.H. Birnie, M.H. Gollob, Rapid genetic testing
facilitating the diagnosis of short QT syndrome, Can. J. Cardiol. 25 (4)
(2009) e133ee135.
[22] R. Wilders, A.O. Verkerk, Role of the R1135H KCNH2 mutation in Brugada
syndrome, Int. J. Cardiol. 144 (2009) 149e151.
[23] D. Akdis, A.M. Saguner, A. Medeiros-Domingo, A. Schaller, C. Balmer,
J. Steﬀel, et al., Multiple clinical proﬁles of families with the short QT syn-
drome, Europace 20 (FI1) (2018) f113ef121.
[24] M.D. Perry, S. Wong, C.A. Ng, J.I. Vandenberg, Hydrophobic interactions be-
tween the voltage sensor and pore mediate inactivation in Kv11.1 channels, J.
Gen. Physiol. 142 (3) (2013) 275e288.
[25] J.P. Lees-Miller, J.O. Subbotina, J. Guo, V. Yarov-Yarovoy, S.Y. Noskov,
H.J. Duﬀ, Interactions of H562 in the S5 helix with T618 and S621 in the
pore helix are important determinants of hERG1 potassium channel structure
and function, Biophys. J. 96 (9) (2009) 3600e3610.
[26] W. Wang, R. MacKinnon, Cryo-em structure of the open human ether-a-go-
go-related Kþ channel hERG, Cell 169 (3) (2017) 422e430.
[27] A. El Harchi, M.J. McPate, Y.H. Zhang, H. Zhang, J.C. Hancox, Action po-
tential clamp and chloroquine sensitivity of mutant Kir2.1 channels respon-
sible for variant 3 short QT syndrome, J. Mol. Cell. Cardiol. 137 (2009)
83e85.
[28] Y.H. Zhang, C.K. Colenso, R.B. Sessions, C.E. Dempsey, J.C. Hancox, The
hERG Kþ channel S4 domain L532P mutation: characterization at 37 degrees
C, Biochim. Biophys. Acta 1808 (10) (2011) 2477e2487.
[29] Y. Zhang, C.K. Colenso, A. El Harchi, H. Cheng, H.J. Witchel,
C.E. Dempsey, et al., Interactions between amiodarone and the hERG potas-
sium channel pore determined with mutagenesis and in silico docking, Bio-
chem. Pharmacol. 113 (2016) 24e35.
[30] Y.H. Zhang, H. Cheng, V.A. Alexeenko, C.E. Dempsey, J.C. Hancox, Char-
acterization of recombinant hERG Kþ channel inhibition by the active metab-
olite of amiodarone desethyl-amiodarone, J. Electrocardiol. 43 (5) (2010)
440e448.
[31] A.A. Paul, H.J. Witchel, J.C. Hancox, Inhibition of heterologously expressed
HERG potassium channels by ﬂecainide and comparison with quinidine, prop-
afenone and lignocaine, Br. J. Pharmacol. 136 (2002) 717e729.on.2019.e01429
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
27 https://doi.org/10.1016/j.heliy
2405-8440/ 2019 The Auth
(http://creativecommons.org/li
Article Nowe01429[32] J.M. Ridley, J.T. Milnes, Y.H. Zhang, H.J. Witchel, J.C. Hancox, Inhibition of
HERG Kþ current and prolongation of the Guinea-pig ventricular action po-
tential by 4-aminopyridine, J. Physiol. 549 (Pt 3) (2003) 667e672.
[33] D. Melgari, K.E. Brack, C. Zhang, Y. Zhang, A. El Harchi, J.S. Mitcheson, et
al., hERG potassium channel blockade by the HCN channel inhibitor brady-
cardic agent ivabradine, J. Am. Heart Assoc. 4 (4) (2015).
[34] M.J. McPate, H. Zhang, I. Ideniran, J.M. Cordeiro, H.J. Witchel, J.C. Hancox,
Comparative eﬀects of the short QT N588K mutation at 37oC on hERG Kþ
channel current during ventricular, Purkinje ﬁbre and atrial action potentials:
an action potential clamp study, J. Physiol. Pharmacol. 60 (2009) 23e41.
[35] A. El Harchi, H. Zhang, J.C. Hancox, The S140G KCNQ1 atrial ﬁbrillation
mutation aﬀects ’I(KS)’ proﬁle during both atrial and ventricular action poten-
tials, J. Physiol. Pharmacol. 61 (6) (2010) 759e764.
[36] M.V. Helliwell, Y. Zhang, A. El Harchi, C. Du, J.C. Hancox, C.E. Dempsey,
Structural implications of hERG Kþ channel block by a high aﬃnity
minimally-structured blocker, J. Biol. Chem. 293 (18) (2018) 7040e7057.
[37] J.R. Whicher, R. MacKinnon, Structure of the voltage-gated Kþ channel Eag1
reveals an alternative voltage sensing mechanism, Science 353 (6300) (2016)
664e669.
[38] A. Sali, T.L. Blundell, Comparative protein modelling by satisfaction of
spatial restraints, J. Mol. Biol. 234 (3) (1993) 779e815.
[39] R. Laskowski, M.W. MacArthur, D.S. Moss, J.M. Thornton, PROCHECK: a
program to check the stereochemical quality of protein structures, J. Appl.
Crystallogr. 26 (1993) 283e291.
[40] J.T. Milnes, H.J. Witchel, J.L. Leaney, D.J. Leishman, J.C. Hancox, Investi-
gating dynamic protocol-dependence of hERG potassium channel inhibition
at 37oC: cisapride versus dofetilide, J. Pharmacol. Toxicol. Methods 61 (2)
(2010) 178e191.
[41] C. Giustetto, R. Schimpf, A. Mazzanti, C. Scrocco, P. Maury, O. Anttonen, et
al., Long-term follow-up of patients with short QT syndrome, J. Am. Coll.
Cardiol. 58 (6) (2011) 587e595.
[42] P. Brugada, Short QT syndrome and hydroquinidine: rare diseases and unavai-
lable drugs, J. Am. Coll. Cardiol. 70 (24) (2017) 3016e3017.
[43] J.C. Hancox, D.G. Whittaker, C. Du, A.G. Stuart, H. Zhang, Emerging thera-
peutic targets in the short QT syndrome, Expert Opin. Ther. Targets 22 (5)
(2018) 439e451.on.2019.e01429
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
28 https://doi.org/10.1016/j.heliy
2405-8440/ 2019 The Auth
(http://creativecommons.org/li
Article Nowe01429[44] G.E. Kirsch, E.S. Trepakova, J.C. Brimecombe, S.S. Sidach, H.D. Erickson,
M.C. Kochan, et al., Variability in the measurement of hERG potassium chan-
nel inhibition: eﬀects of temperature and stimulus pattern, J. Pharmacol. Tox-
icol. Methods 50 (2) (2004) 93e101.
[45] J.A. Yao, X. Du, D. Lu, R.L. Baker, E. Daharsh, P. Atterson, Estimation of
potency of HERG channel blockers: impact of voltage protocol and tempera-
ture, J. Pharmacol. Toxicol. Methods 52 (1) (2005) 146e153.
[46] A. Butler, Y. Zhang, A.G. Stuart, C.E. Dempsey, J.C. Hancox, Action poten-
tial clamp characterization of the S631A hERG mutation associated with short
QT syndrome, Phys. Rep. 6 (17) (2018), e13845.
[47] A. Zou, Q.P. Xu, M.C. Sanguinetti, A mutation in the pore region of HERG K
channels expressed in Xenopus oocytes reduces rectiﬁcation by shifting the
voltage dependence of inactivation, J. Physiol. 509 (1) (1998) 129e137.
[48] J.A. Ballesteros, X. Deupi, M. Olivella, E.E. Haaksma, L. Pardo, Serine and
threonine residues bend alpha-helices in the chi(1) ¼ g(-) conformation, Bio-
phys. J. 79 (5) (2000) 2754e2760.
[49] X. Deupi, M. Olivella, A. Sanz, N. Dolker, M. Campillo, L. Pardo, Inﬂuence
of the g- conformation of Ser and Thr on the structure of transmembrane he-
lices, J. Struct. Biol. 169 (1) (2010) 116e123.
[50] A.S. Dore, K. Okrasa, J.C. Patel, M. Serrano-Vega, K. Bennett, R.M. Cooke,
et al., Structure of class C GPCR metabotropic glutamate receptor 5 transmem-
brane domain, Nature 511 (7511) (2014) 557e562.
[51] M.D. Perry, C.A. Ng, J.I. Vandenberg, Pore helices play a dynamic role as in-
tegrators of domain motion during Kv11.1 channel inactivation gating, J. Biol.
Chem. 288 (16) (2013) 11482e11491.
[52] C.K. Colenso, R.B. Sessions, Y.H. Zhang, J.C. Hancox, C.E. Dempsey, Inter-
actions between voltage sensor and pore domains in a hERG Kþ channel
model from molecular simulations and the eﬀects of a voltage sensor mutation,
J. Chem. Inf. Model. 53 (6) (2013) 1358e1370.
[53] I. Adeniran, M.J. McPate, H.J. Witchel, J.C. Hancox, H. Zhang, Increased
vulnerability of human ventricle to re-entrant excitation in hERG-linked
variant 1 short QT syndrome, PLoS Comput. Biol. 7 (12) (2011), e1002313.
[54] J.C. Hancox, A.G. Stuart, Rational prediction of pharmacological treatment
options for a novel KCNH2-linked variant of the short QT syndrome, Ann.
Circ. 3 (1) (2018) 008e009.on.2019.e01429
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
29 https://doi.org/10.1016/j.heliy
2405-8440/ 2019 The Auth
(http://creativecommons.org/li
Article Nowe01429[55] D.G. Whittaker, H. Ni, A.P. Benson, J.C. Hancox, H. Zhang, Computational
analysis of the mode of action of disopyramide and quinidine on hERG-linked
short QT syndrome in human ventricles, Front. Physiol. 8 (2017) 759.
[56] J.C. Hancox, A.J. Levi, H.J. Witchel, Time course and voltage dependence of
expressed HERG current compared with native ’rapid’ delayed rectiﬁer K cur-
rent during the cardiac ventricular action potential, Pﬂueg. Arch. Eur. J. Phys-
iol. 436 (1998) 843e853.
[57] H. Halkin, Z. Vered, P. Millman, B. Rabinowitz, H.N. Neufeld, Steady-state
quinidine concentration: role in prophylactic therapy following acute myocar-
dial infarction, Isr. J. Med. Sci. 15 (1979) 583e587.
[58] C. Giustetto, M.F. Di, C. Wolpert, M. Borggrefe, R. Schimpf, P. Sbragia, et
al., Short QT syndrome: clinical ﬁndings and diagnostic-therapeutic implica-
tions, Eur. Heart J. 27 (20) (2006) 2440e2447.
[59] J.P. Lees-Miller, Y. Duan, G.Q. Teng, H.J. Duﬀ, Molecular determinant of
high aﬃnity dofetilide binding to HERG1 expressed in Xenopus oocytes:
involvement of S6 sites, Mol. Pharmacol. 57 (2000) 367e374.
[60] M.J. Perrin, P.W. Kuchel, T.J. Campbell, J.I. Vandenberg, Drug binding to the
inactivated state is necessary but not suﬃcient for high-aﬃnity binding to hu-
man ether-a-go-go-related gene channels, Mol. Pharmacol. 74 (2008)
1443e1452.
[61] W. Wu, A. Gardner, M.C. Sanguinetti, Cooperative subunit interactions
mediate fast C-type inactivation of hERG1 Kþ channels, J. Physiol. 592
(20) (2014) 4465e4480.
[62] E.M. Jones, E.C. Roti Roti, J. Wang, G.A. Robertson, Cardiac IKr channels
minimally comprise hERG 1a and 1b subunits, J. Biol. Chem. 279 (2004)
44690e44694.
[63] D.K. Jones, F. Liu, R. Vaidyanathan, L.L. Eckhardt, M.C. Trudeau,
G.A. Robertson, hERG 1b is critical for human cardiac repolarization, Proc.
Natl. Acad. Sci. U. S. A. 111 (50) (2014) 18073e18077.
[64] M.J. McPate, H. Zhang, J.M. Cordeiro, C.E. Dempsey, H.J. Witchel,
J.C. Hancox, hERG1a/1b heteromeric currents exhibit ampliﬁed attenuation
of inactivation in variant 1 short QT syndrome, Biochem. Biophys. Res. Com-
mun. 386 (1) (2009) 111e117.on.2019.e01429
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
